Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Price Target from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received a consensus rating of “Buy” from the seven analysts that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $66.75.

A number of research firms have recently issued reports on ARCT. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research report on Monday, January 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research report on Monday, December 16th.

Arcturus Therapeutics Trading Down 1.7 %

NASDAQ:ARCT opened at $17.12 on Friday. The stock has a market capitalization of $463.78 million, a PE ratio of -7.71 and a beta of 2.63. Arcturus Therapeutics has a 1-year low of $14.30 and a 1-year high of $45.00. The firm has a fifty day simple moving average of $17.28 and a 200 day simple moving average of $19.67.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.44. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The company had revenue of $41.67 million for the quarter, compared to analyst estimates of $49.16 million. During the same period in the previous year, the business earned ($0.61) EPS. On average, equities analysts predict that Arcturus Therapeutics will post -2.31 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. nVerses Capital LLC bought a new stake in shares of Arcturus Therapeutics in the third quarter valued at about $42,000. China Universal Asset Management Co. Ltd. grew its position in shares of Arcturus Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,201 shares of the biotechnology company’s stock worth $121,000 after purchasing an additional 2,038 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Arcturus Therapeutics during the second quarter worth approximately $142,000. Point72 DIFC Ltd bought a new stake in shares of Arcturus Therapeutics in the second quarter valued at approximately $188,000. Finally, SG Americas Securities LLC bought a new stake in shares of Arcturus Therapeutics in the third quarter valued at approximately $191,000. 94.54% of the stock is owned by institutional investors and hedge funds.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.